You are here
Articles
Posted on Wednesday, December 5, 2018 - 2:14pm
Posted on Sunday, November 11, 2018 - 5:02pm
A study is being sponsored by UCL School of Pharmacy in London to look into the acceptability of web-based video consultations for patients who are receiving treatment for CML at University College London Hospital UCLH.
Posted on Thursday, September 27, 2018 - 4:07pm
Researchers at the University of Glasgow’s Institute of Cancer Sciences have been awarded £3.1 million by Cancer Research UK to lead a first-of-its-kind pioneering study to help find new treatments for patients with...
Posted on Tuesday, August 21, 2018 - 5:25pm
In chronic myeloid leukemia (CML) treatment response is determined by measurements of BCR-AB1L transcripts in peripheral blood by quantitative real-time PCR (qRT-PCR) and a 2–5 fold increase is considered a warning sign.
Posted on Tuesday, August 21, 2018 - 5:23pm
Dasatinib's bioavailability is highly dependent on gastric pH. When proton-pump inhibitors (PPIs) are co-administered with dasatinib, absorption is significantly reduced.
Posted on Tuesday, August 14, 2018 - 4:40pm
The UK CML Patient Conference: '22/09 World CML Day' Saturday 22nd September 2018.
The event has now taken place, and video recordings of the main presentations are available on this page.
Posted on Sunday, July 29, 2018 - 5:12pm
Marlise R. Luskin Published online: 23 Jul 2018
Posted on Monday, July 9, 2018 - 2:21pm
"There are preliminary data that CML patients who maintain TFR successfully after TKI cessation have higher NK cell numbers and function compared with those who relapse off-treatment, further supporting the importance...
Posted on Saturday, May 5, 2018 - 3:17pm
"At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months.
Posted on Thursday, March 1, 2018 - 3:54pm
Do you shop on Amazon UK?
Posted on Wednesday, February 28, 2018 - 1:11pm
Authors: Moshe Talpaz MD, Giuseppe Saglio MD, Ehab Atallah MD, Philippe Rousselot MD, PhDFirst published: 25 January 2018
Conclusions
Posted on Tuesday, February 27, 2018 - 10:56am
Nilotinib is a second-generation TKI that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib vs imatinib (...
Posted on Thursday, February 22, 2018 - 12:04pm
Stuart L. Goldberg, Michael Savona, Michael J. Mauro
Conclusions and Future Directions
Posted on Tuesday, February 20, 2018 - 10:32am
Discussion and Results.
Posted on Friday, December 22, 2017 - 5:25pm
Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)
- ‹ previous
- 5 of 33
- next ›